Pay in 4 interest-free payments of $7.25 Learn more
Ships within 48 hours · Estimated delivery Aug 16 - Aug 21
In 2005, the Food and Drug Administration approved the first-ever GLP-1 agonist, exenatide (Byetta)
Why It Works: Modulates nitric oxide bioavailability at the eNOS level, helping stabilize the balance between vasodilation and vasoconstriction in injured tissue Upregulates VEGFR2 expression and drives VEGF-mediated angiogenesis, supporting new blood vessel formation at injury sites Protects cell-matrix adhesion through FAK-paxillin signaling and appears to dampen local inflammatory cascades via NF-B modulation Best For: Tendon, ligament, and soft-tissue injury recovery, along with gut-lining and gastrointestinal repair research Typical Protocol: Preclinical/research protocols commonly reference 200-500 mcg per day via subcutaneous injection, split into one or two daily doses (with 250 mcg once or twice daily being a frequently cited starting range)
It's filled out about a patient, it's scored by you or the patient, and you could identify the phenotype and then target your treatment directly to what the issues are that patient is facing
What you should consider: The liquid can leave behind an unpleasant aftertaste and its considerably more expensive than other supplements
US$ 25.54
US$ 29.36
US$ 21.46
US$ 20.52
US$ 24.50
US$ 24.66
US$ 28.74
US$ 25.47
US$ 23.86
US$ 25.03
